2SPD-018 Adjusted indirect comparison between plozasiran and zodasiran in mixed hyperlipidemia
Year: 2025
Type: conference-paper
Abstract: Background and Importance Plozasiran and zodasiran are RNA interference agents developed for the treatment of mixed hyperlipidemia. No direct comparisons between these drugs have been performed. Aim and Objectives To conduct adjusted indirect comparisons (AICs) on efficacy between plozasiran and zodasiran in mixed hyperlipidemia. Material and Methods A search was developed in Pubmed database to select pivotal randomised clinical trials (RCTs) including plozasiran and zodasiran in mixed hyperlipidemia. These RCTs had to presented comparable populations, follow-up periods, endpoints and comparator arms. AICs of regimens with best benefit-risk balance were developed using Bucher’s method on the following endpoints: percentage change in plasma levels from baseline to week 24 of fasting triglyceride, non-HDL cholesterol, ApoB, LDL cholesterol, HDL cholesterol, remnant cholesterol and lipoprotein (a). The absolute risk reduction (ARR) was calculated for AICs. Results Two phase II RCTs were selected, one of each drug. A total of 557 patients were included. Doses of plozasiran 25 mg quarterly (PLOZ-25q) and zodasiran 200 mg (ZOD-200) were selected based on their superior risk-benefit balance. Placebo was common comparator. AIC limitations: short patient follow-up and minor differences in population characteristics (percentage of high-intensity statins and fibrates received). The results of the trials and AICs are shown in table 1. Conclusion and Relevance Significant favourable differences on differing surrogate endpoints were found for PLOZ-25q (HDL cholesterol) and ZOD-200 (non-HDL cholesterol, LDL cholesterol, remnant cholesterol) in mixed hyperlipidaemia. RCTs with harder endpoints and longer follow-up are needed to establish better therapeutic positioning. References and/or Acknowledgements Conflict of Interest No conflict of interest
Institution: Servicio Extremeño de Salud
Language: English
Subfield: Surgery
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4408376804